RxDoctor Payments Data

Monika Chapman, NP

Women's Health · Wilmington, DENPI 1588332670

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.

$1,107in general payments, 2019–2025

Across 58 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$153
  • Sage Therapeutics, LLC$133
  • Myovant Sciences Inc.$104
  • Exeltis, USA Inc.$95
  • Shield Therapeutics Inc$81
  • Mayne Pharma Commercial LLC$72
  • plus $470 from 12 others

What the payments were for

  • Food & beverage$1,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,107 in reported general payments places this provider in the 75th percentile of 29 women's health providers in Delaware.

See all women's health providers in Delaware

Medicare billing

Part B allowed, 2024
$4,857
Medicare patients
80
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol35$2,229
Metronidazole13$202
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$144
Alendronate Sodium21$138
Fluconazole19$58

Paid to pharmacies, not to this prescriber.

Other women's health in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →